Ami Organics revenue from operations for Q2 FY23 grew by 20.2% YoY to Rs. 147 crore whereas profit after tax (PAT) for the quarter was at Rs. 19 crore up 9% on YoY basis.

Export at 58% whereas domestic business at 42%. The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23.

Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited said, “We continue our robust trajectory with 20% YoY growth during Q2, primarily driven by a significant increase in the Advanced pharmaceutical intermediate business which grew by 25% YoY. That said, the company witnessed a flattish growth in the specialty chemicals business. Our margins continue to strengthen as we keep tight control on cost as well as because of lower freight rates. I believe margins will continue to see improvement in the coming quarters."

"I am delighted to announce that we have successfully developed Methyl Salicylate using flow technology which is expected to commercialize from Q3 onwards. This shift in manufacturing technology has resulted in a considerable reduction in production time, 3x capacity expansion, and cost savings of around 5-7%. Electrolyte additives continue to see good inquiries from clients across the globe and we expect to commercialize the product before the end of FY23," commented Patel. 

"Overall, I remain optimistic about our business growth in the coming quarters and years on the back of various strong growth levers,” added Patel.

Ami Organics is a R&D driven manufacturer of specialty chemicals with varied end usage, focussed on the development and manufacturing of advanced pharmaceutical intermediates for regulated markets and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals. Ami has developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.